Dhara N. Amin

1.8k total citations
19 papers, 1.2k citations indexed

About

Dhara N. Amin is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Dhara N. Amin has authored 19 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 12 papers in Oncology and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Dhara N. Amin's work include HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Angiogenesis and VEGF in Cancer (4 papers). Dhara N. Amin is often cited by papers focused on HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Angiogenesis and VEGF in Cancer (4 papers). Dhara N. Amin collaborates with scholars based in United States, France and Grenada. Dhara N. Amin's co-authors include Michael Klagsbrun, Mark M. Moasser, Marcia R. Campbell, Diane R. Bielenberg, Yasuhiro Hida, Alan F. Flint, Kyoko Hida, Cynthia C. Morton, Dipak Panigrahy and Kyoko Hida and has published in prestigious journals such as The Journal of Immunology, PLoS ONE and Cancer Cell.

In The Last Decade

Dhara N. Amin

17 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dhara N. Amin United States 12 782 684 334 284 177 19 1.2k
Maria Sundvall Finland 20 1.2k 1.5× 949 1.4× 289 0.9× 364 1.3× 303 1.7× 33 1.8k
Kedar S. Vaidya United States 18 1.1k 1.3× 550 0.8× 481 1.4× 132 0.5× 174 1.0× 35 1.6k
Lily Yen Canada 17 861 1.1× 639 0.9× 184 0.6× 245 0.9× 109 0.6× 18 1.3k
Matthew T. Harbison United States 8 853 1.1× 924 1.4× 362 1.1× 122 0.4× 275 1.6× 8 1.6k
Noa Ben-Baruch Israel 16 524 0.7× 757 1.1× 384 1.1× 237 0.8× 232 1.3× 38 1.3k
Maria Niewolna United States 18 1.0k 1.3× 1.2k 1.8× 304 0.9× 290 1.0× 351 2.0× 23 2.0k
Keltouma Driouch France 24 1.3k 1.6× 687 1.0× 425 1.3× 120 0.4× 264 1.5× 41 1.8k
Archana Narasanna United States 9 576 0.7× 817 1.2× 181 0.5× 368 1.3× 362 2.0× 12 1.3k
WJ Gullick United Kingdom 18 751 1.0× 1.1k 1.7× 307 0.9× 544 1.9× 269 1.5× 26 1.6k
Franck Assayag France 17 549 0.7× 668 1.0× 388 1.2× 127 0.4× 176 1.0× 35 1.3k

Countries citing papers authored by Dhara N. Amin

Since Specialization
Citations

This map shows the geographic impact of Dhara N. Amin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dhara N. Amin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dhara N. Amin more than expected).

Fields of papers citing papers by Dhara N. Amin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dhara N. Amin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dhara N. Amin. The network helps show where Dhara N. Amin may publish in the future.

Co-authorship network of co-authors of Dhara N. Amin

This figure shows the co-authorship network connecting the top 25 collaborators of Dhara N. Amin. A scholar is included among the top collaborators of Dhara N. Amin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dhara N. Amin. Dhara N. Amin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Monti, Daniela, et al.. (2025). Patient Language and Differences in Administration of Analgesia for Pelvic Pain. Women s Health Issues. 35(4). 261–266.
2.
Amin, Dhara N., et al.. (2025). A Qualitative Analysis of Patient Experiences Using Semaglutide 2.4 mg for Weight Loss. Obesity Science & Practice. 11(4). e70085–e70085.
3.
Yen, Ivana, Fergus Shanahan, Mark Merchant, et al.. (2018). Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors. Cancer Cell. 34(4). 611–625.e7. 47 indexed citations
4.
Amin, Dhara N., Jason Oeh, Lisa Musick, et al.. (2018). Abstract 880: Anti-tubulin antibody drug conjugates potentiate venetoclax activity in non-Hodgkin lymphoma by targeting MCL-1. Cancer Research. 78(13_Supplement). 880–880. 4 indexed citations
5.
Campbell, Marcia R., Hui Zhang, Ana Ruiz-Sáenz, et al.. (2016). Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin. Breast Cancer Research and Treatment. 155(3). 431–440. 15 indexed citations
6.
Amin, Dhara N., Deepika Ahuja, Paul Yaswen, & Mark M. Moasser. (2015). A TORC2–Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers. Molecular Cancer Therapeutics. 14(12). 2805–2817. 4 indexed citations
7.
Chang, Young Hwan, James E. Korkola, Dhara N. Amin, et al.. (2015). Disentangling Multidimensional Spatio-Temporal Data into Their Common and Aberrant Responses. PLoS ONE. 10(4). e0121607–e0121607. 2 indexed citations
8.
9.
Amin, Dhara N., Natalia Sergina, Lionel Lim, Andrei Goga, & Mark M. Moasser. (2012). HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. Biochemical Journal. 447(3). 417–425. 44 indexed citations
10.
Coma, Sílvia, Dhara N. Amin, Akio Shimizu, et al.. (2010). Id2 Promotes Tumor Cell Migration and Invasion through Transcriptional Repression of Semaphorin 3F. Cancer Research. 70(9). 3823–3832. 70 indexed citations
11.
Campbell, Marcia R., Dhara N. Amin, & Mark M. Moasser. (2010). HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy. Clinical Cancer Research. 16(5). 1373–1383. 147 indexed citations
12.
Amin, Dhara N., Marcia R. Campbell, & Mark M. Moasser. (2010). The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Seminars in Cell and Developmental Biology. 21(9). 944–950. 117 indexed citations
13.
Amin, Dhara N., Natalia Sergina, Deepika Ahuja, et al.. (2010). Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver. Science Translational Medicine. 2(16). 16ra7–16ra7. 135 indexed citations
14.
Miksa, Michael, Rongqian Wu, Hidefumi Komura, et al.. (2009). Immature dendritic cell-derived exosomes rescue septic animals via milk fat globule epidermal growth factor VIII. The Journal of Immunology. 183(12). 8295–8295. 2 indexed citations
15.
Amin, Dhara N., Diane R. Bielenberg, Eugene Lifshits, John V. Heymach, & Michael Klagsbrun. (2008). Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvascular Research. 76(1). 15–22. 47 indexed citations
16.
Amin, Dhara N., Kyoko Hida, Diane R. Bielenberg, & Michael Klagsbrun. (2006). Tumor Endothelial Cells Express Epidermal Growth Factor Receptor (EGFR) but not ErbB3 and Are Responsive to EGF and to EGFR Kinase Inhibitors. Cancer Research. 66(4). 2173–2180. 178 indexed citations
17.
Amin, Dhara N., David Tuck, & David F. Stern. (2005). Neuregulin-regulated gene expression in mammary carcinoma cells. Experimental Cell Research. 309(1). 12–23. 21 indexed citations
18.
Hida, Kyoko, Yasuhiro Hida, Dhara N. Amin, et al.. (2004). Tumor-Associated Endothelial Cells with Cytogenetic Abnormalities. Cancer Research. 64(22). 8249–8255. 366 indexed citations
19.
Amin, Dhara N., Archibald S. Perkins, & David F. Stern. (2003). Gene expression profiling of ErbB receptor and ligand-dependent transcription. Oncogene. 23(7). 1428–1438. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria Sundvall Breakdown of academic impact, for papers by Kedar S. Vaidya Breakdown of academic impact, for papers by Lily Yen Breakdown of academic impact, for papers by Matthew T. Harbison Breakdown of academic impact, for papers by Noa Ben-Baruch Breakdown of academic impact, for papers by Maria Niewolna Breakdown of academic impact, for papers by Keltouma Driouch Breakdown of academic impact, for papers by Archana Narasanna Breakdown of academic impact, for papers by WJ Gullick Breakdown of academic impact, for papers by Franck Assayag
Rankless by CCL
2026